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Atrial fibrillation (AF) affects up to 5 million people in the United States, and data 
suggest that as the population ages, the incidence will continue to increase1,2. 
The rate of ischemic stroke among patients with nonvalvular AF averages 5% 
per year3. The rate of death among patients with AF is about double that among 
patients with normal sinus rhythm3. The overall cost of treating recurrent AF has 
been estimated to be more than 6.5 billion (dollars) per year4. Importantly, as 
we will discuss later, it seems, that not only prevalence of AF is progressively 
increasing but also the risk profile of patients with AF.  
 
AF is usually a progressive disease. The natural history often begins with 
infrequent episodes of limited duration termed paroxysmal AF (often defined as 
episodes that terminate spontaneously within 1 week). Such episodes then tend 
to become more frequent and longer in duration, progressing to persistent AF 
(which fails to terminate spontaneously within 7 days and may require 
cardioversion) or permanent AF (if the arrhythmia lasts for more than 1 year and 
cardioversion either has not been attempted or has failed). Symptoms include 
palpitations, shortness of breath, and fatigue; particularly for symptomatic 
patients, AF has adverse effects on quality of life3. Outstandingly, AF confers a 
5-fold risk of stroke, and one in five of all strokes are attributed to this 
arrhythmia. In this regard, the identification of various stroke clinical risk factors 
has led to the publication of various stroke risk schemes3. Most have (artificially) 
categorized stroke risk into ‘high’, ‘moderate’, and ‘low’ risk strata. The simplest 




hypertension, age, diabetes, stroke (doubled)] risk index evolved from the AF 
Investigators and Stroke Prevention in AF (SPAF) Investigators criteria, and is 
based on a point system in which 2 points are assigned for a history of stroke or 
TIA and 1 point each is assigned for age ≥ 75 years, a history of hypertension, 
diabetes, or recent cardiac failure. 
Thus, the CHADS2 stroke risk stratification scheme should be used as an initial, 
rapid, and easy-to-remember means of assessing stroke risk. In patients with a 
CHADS2 score ≥2, chronic OAC therapy with a VKA is recommended in a 
dose-adjusted approach to achieve an international normalized ratio (INR) 
target of 2.5. 
Recently, in the last guidelines for the management of AF other ‘clinically 
relevant non-major’ risk factors (previously referred to as ‘less validated risk 
factors’) include female sex, age 65 – 74 years, and vascular disease 
(specifically, myocardial infarction, complex aortic plaque and periferical artery 
disease (PAD)). Note that risk factors are cumulative, and the simultaneous 
presence of two or more ‘clinically relevant non-major’ risk factors would justify 
a stroke risk that is high enough to require anticoagulation. This risk factor-
based approach for patients with non-valvular AF can also be expressed as an 
acronym, CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 
(doubled), diabetes, stroke (doubled), vascular disease, age 65 – 74, and sex 
category (female)]. This scheme is based on a point system in which 2 points 
are assigned for a history of stroke or TIA, or age ≥75; and 1 point each is 
assigned for age 65–74 years, a history of hypertension, diabetes, recent 
cardiac failure, vascular disease (myocardial infarction, complex aortic plaque, 





angiographic evidence of PAD, etc.), and female sex. Thus, this acronym 
(CHA2DS2-VASc) extends the CHADS2 scheme by considering additional 
stroke risk factors that may influence a decision whether or not to anticoagulate. 
The true magnitude of these recommendations has not yet been quantified and 
will be also analysed in detail along this pages. 
 
The electrophysiological basis of AF requires both a trigger that initiates the 
dysrhythmia and a substrate that can sustain it5,6. Althougt AF can be 
precipitated by several causes as we will discuss later on (channelopathiesas, 
slow auriculoventricular nodal tachycardia, etc), the most common triggers of 
AF are ectopic atrial beats that arise from the muscle sleeves of the pulmonary 
veins7,8. These triggers may be provoked by the intrinsic activity of cardiac 
ganglionic plexuses, which are clustered in the vicinity of the pulmonary vein–
left atrial junction9,10. The pulmonary vein–left atrial junction and an enlarged 
atrium harboring fibrosis and inflammation serve as the substrate for sustaining 
wavelets of AF. With persistence of AF, a further electrophysiological change in 
the atria - namely, shortening of the refractory period of the atrial muscle - 
occurs and predisposes to the development of other triggers and wavelets. This 
process results in perpetuation of AF and in a greater predisposition to AF. 
Maintenance of sinus rhythm can reverse these changes and mechanisms. 
Hence, AF begets atrial fibrillation, and sinus rhythm begets sinus rhythm11-13. 
Whether to restore and maintain sinus rhythm (“rhythm control”) or allow AF to 
continue while controlling ventricular rate (“rate control”) remains a key decision 
steeped in controversy. Given the poor outcomes associated with AF3, rhythm 




death or is simply a marker of risk. Despite the association of AF with excess 
morbidity and mortality, the Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) trial and multiple other studies failed to demonstrate 
reduction in death, stroke, or hospitalization with rhythm control compared with 
rate control, assuming appropriate anticoagulation as part of either strategy14-18. 
Even in patients with systolic dysfunction and clinical heart failure, in whom AF 
is a predictor of death and frequent cause of decompensation, the Atrial 
Fibrillation and Congestive Heart Failure trial identified no difference in overall 
survival, cardiovascular death, worsened heart failure, or stroke at 37 months 
with rhythm control19. 
The apparent discrepancy between the poor outcomes associated with AF in 
epidemiologic studies and the failure of multiple trials to demonstrate a 
substantial benefit from a rhythm-control strategy reflect the limited efficacy and 
adverse effects of the available antiarrhythmic medications used in these 
studies to maintain sinus rhythm. The proportion of patients actually achieving 
sinus rhythm with antiarrhythmic drugs in randomized trials, ranging from 26% 
to 63%14-18, illustrates this limited efficacy. Nearly all antiarrhythmic medications 
carry a risk of ventricular proarrhythmic toxicity. In addition, the predominant 
antiarrhythmic drug in these studies, amiodarone (used in 62.8% of patients in 
the rhythm control arm of AFFIRM14 and in 82% of patients in Atrial Fibrillation 
and Congestive Heart Failure19), has substantial extracardiac toxicity, including 
pulmonary and hepatic toxicity, thyroid dysfunction, and bradycardia. 
Furthermore, because the “rate versus rhythm control” trials generally involved 
older patients with comorbidities, the results cannot be extrapolated to younger, 





with a rate-control strategy. The results of these studies should therefore not be 
interpreted as a lack of benefit of restoring sinus rhythm, but rather that the 
toxicity and limited efficacy of available antiarrhythmic medications make their 
routine use no better than rate control to achieve freedom from stroke and 
death. In support of this concept, a post hoc analysis of AFFIRM demonstrated 
that sinus rhythm was associated with a lower risk of death independently of the 
medications used compared with the presence of AF, and after adjustment for 
the rhythm, antiarrhythmic medications increased mortality20. 
 
Antiarrhythmic drugs are considered the first-line treatment for maintenance of 
sinus rhythm. However, the efficacy of these agents is not favorable, with only 
50% of patients so treated maintaining sinus rhythm after 1 year of follow-
up21,22. In addition, as we pointed out previously, the side effects of 
antiarrhythmic drugs are not trivial. In a recent meta-analysis, these side effects 
included treatment-related death in 0.5% of patients, torsades de pointes in 
0.7%, neuropathy in 5.0%, and thyroid dysfunction in 3.3%23. Less serious side 
effects such as gastrointestinal symptoms occur more frequently and may have 
a substantial effect on quality of life.   
In regard with the medical treatment is important to highlight that in some 
situations AF coexist with common atrial flutter (AFl). As a matter of fact it is a 
well-recognized and commonly encountered occurrence in the clinical setting3. 
It has been shown that antiarrhythmic drugs can organize AF into AFl14. The 
administration of AAD to patients with AF allows for the formation of these lines 
of functional block and hence organization into AFl. Hybrid therapy is a 




(CTI) and continued pharmacologic therapy when treatment with Class I or III 
AAD organizes AF into AFl. Numerous studies have shown hybrid therapy to be 
an effective treatment with AF recurrences rates ranging between 11 and 27%3. 
However, these studies have been limited by short follow-up periods. In the 
present thesis, we aimed to focus also on the AF recurrence, stroke and death 
during long-term follow-up in a cohort of patients with AF to AFI conversion 
following treatment with antiarrhythmic drugs - AFl compared with patients with 
coexisting AF and AFl after radiofrequency catheter ablation of CTI. 
  
Catheter ablation is indicated to prevent the recurrence of symptomatic AF in 
patients in whom medical therapy has been ineffective. AF ablation is a 
therapeutic technique that uses radiofrequency energy or freezing to destroy 
atrial tissue that is involved in the propagation of the dysrhythmia. 
Radiofrequency ablation generates an alternating electrical current that passes 
through myocardial tissue, creating heat energy that conducts to deeper tissue 
layers. At temperatures of 50°C or higher, most tissues undergo irreversible 
coagulation necrosis and then evolve into nonconducting myocardial scar 
tissue24,25. Cryoablation destroys tissue by freezing.  
The principal objective of AF ablation is the electrical disconnection of the 
pulmonary-vein triggers from the atrial substrate (often called “pulmonary-vein 
isolation”)26,27. To achieve this goal, ablation is performed around the pul- 
monary-vein orifice. Ablation of sites beyond the pulmonary vein–left atrial 
junction in the atrial substrate itself, targeting so-called complex fractionated 
electrograms, is not necessary in paroxysmal AF but may be very important in 





Several randomized trials have shown superior outcomes for radiofrequency 
ablation as compared with antiarrhythmic drug therapy28-35. For example, in one 
trial, 198 patients with paroxysmal AF in whom antiarrhythmic drug therapy had 
previously failed were randomly assigned to either radiofrequency ablation or 
antiarrhythmic drug therapy with other agents32. Patients assigned to catheter 
ablation received antiarrhythmic drug therapy for the first 6 weeks after 
treatment, and recurrences during this interval were not included in the primary 
trial end point (a so-called blanking period to allow healing of the atrial 
myocardium after the procedure). At 1 year, 86% of the patients assigned to 
catheter ablation and 22% of those assigned to antiarrhythmic drug therapy had 
not had a recurrent atrial tachyarrhythmia (P<0.001). Hospitalizations for 
cardiovascular disease were also less frequent in the ablation group. 
In another trial, 167 patients with drug-resistant paroxysmal AF were randomly 
assigned to ablation or another antiarrhythmic drug33. At 9 months, 63% of the 
patients assigned to catheter ablation and 17% of those assigned to 
antiarrhythmic drug therapy were free of recurrent atrial tachyarrhythmias. 
Patients in the ablation group also had significantly greater improvement in 
quality of life.  
 
Cryoablation has also been shown to be effective. In the STOP AF trial, 245 
patients with paroxysmal AF in whom previous antiarrhythmic drug therapy had 
failed were randomly assigned to treatment with a cryoablation balloon or 
antiarrhythmic drugs. One year after treatment, 69.9% of the patients treated 
with cryoablation had no detectable AF, as compared with 7.3% of those who 




ablation has also been performed in the last years in order to achive pulmonary 
vein isolation, and although results seem to be superior to those obtained 
endocardially, it is subject to potential complications.  
 
A recently published survey reported data on 16,309 patients undergoing AF 
ablation worldwide, including data on adverse events. Almost all the procedures 
in this survey were performed with the use of radiofrequency ablation; 
cryoablation was used in less than 2% of cases. In this survey, the risk of a 
major complication was 4.5%35. The risk of death was 0.15%. 
Cardiac tamponade due to perforation is a potentially life-threatening 
complication occurring in approximately 1.3% of patients undergoing AF 
ablation. Cardiac perforation can be secondary to a misdirected transseptal 
puncture, trauma due to catheter movement, or excessive focal application of 
radiofrequency energy. Direct injury to the phrenic nerve can also occur as a 
result of ablation near the right superior pulmonary vein and superior vena cava. 
Such injury can cause diaphragmatic paralysis. Esophageal injury has been 
reported in approximately 10% of patients; atrioesophageal fistulas are rare 
(occurring in 0.04% of patients) but can be devastating and even lethal33. 
Cerebrovascular thromboembolism has been reported to occur in up to 2% of 
patients33. Thromboembolic complications can arise because of clot or char 
formation on the sheaths and catheters or at the site of ablation. The diagnosis 
is usually made during the procedure, but thromboemboli can occur several 
days later. 
Pulmonary-vein stenosis is a late complication of ablation caused by injury to 





Symptoms of pulmonary-vein stenosis include chest pain, shortness of breath, 
cough, and recurrent lung infections33. The diagnosis is made with the use of 
computed tomographic imaging or magnetic resonance scanning or by means 
of ventilation–perfusion lung scanning. 
Iatrogenic atypical flutter, a type of regular atrial arrhythmia encountered after 
ablation, can result from ablation lines that do not completely isolate the 
pulmonary veins. The occurrence of this complication depends to a large extent 
on the technique of ablation; the incidence ranges from 1.8 to 14.3%. 
Nevertheless, pulmonary vein stenosis has never been described in the setting 
of thoracoscopic approach, were however there is a potential risk of conversion 
to sternotomy, pleural effusion and pneumothorax.  
 
Finally, as abovementioned, although several advances in the field of AF 
ablation have been done in the recent years, fewer progresses have been made 
in the field of AFI ablation procedures. As it well known, the reentrant circuit 
through the CTI is located in the right atrium and the left atrium is then activated 
passively. Therefore, radiofrequency ablation of AFI appears as a reasonable 
approach regarding feasibility, effectiveness, and it is considered as a low 
procedural risk3. Most studies on ablation-related complications concern all 
indications of ablation, however, little is known about the risk of pacemaker 
(PCM) implantation after uneventful successful CTI ablation in the long term 



































 Based on epidemiological studies, AF prevalence has increased significantly 
over the last decade. We hypothesize that a radical change in the risk profile 
for thromboembolic events in patients with AF has additionally ensued, as 
also a change in the use of oral anticoagulants and upstream therapies.  
 
 The most widely used system for the tromboembolic prevention is the 
CHADS2 scale. Due to the limitations of this scale, the current guidelines 
(European Society of Cardiology) emphasize other ‘‘modulating’’ factors that 
were previously not taken into consideration, such as vascular disease or 
female sex, and it proposes a new classification system, the so called 
‘‘CHA2DS2-VASc’’ scale. It is our hypothesis that this new approach wills 
reclassifies a substantial number of patients previously considered ‘‘low’’ or 
‘‘moderate’’ risk into higher categories, with the subsequent increase of the 
indication for OAC.  
 
 Some percentage of patients with AF can have “lone AF,” which can be, in 
certain cases, of hereditary origin. Accordingly, during previous years, 
numerous inherited cardiac syndromes associated with AF have been 
identified, including Brugada syndrome (BS). Moreover, AF can even be the 
first manifestation of latent BS. We postulate that a relevant percetage of 






 At the present time no prospective studies have been conducted in patients 
with AF but absence of heart failure. We assume that rate of admissions due 
to any cause or due to cardiovascular cause in this subgroup of patients are 
higher than in patients without left bundle branch block. 
 
 Evidence supporting the use of digoxine is nowadays a matter of 
controversy, mainly as a rate control in patients with AF. We hypothesize 
that digoxine could be a useful drug in a subgroup of patients, without 
deleterous effect (in terms of cardiovascular mortality and hospital 
admissions).  
 
 We postulate that the so-called “hybrid therapy” (management strategy that 
consists of the ablation of CTI and continued pharmacologic therapy with 
Class I or III AAD), presently established in the ESC guidelines, is not an 
effective therapy for long-term control of AF. 
 
 Finally, we hypothesize that in patients with history of CTI ablation for 
common AFL, ECG Intraventricular conduction disturbance and slow 
ventricular response at the time of the ablation might be strong predictors of 





































 To define trends in AF prevalence and its medical management using recent 
data based on data from two cross-sectional studies performed in a 
European country in 1999 and 2009. 
 
 To analyze the impact of classifying patients with AF according to the 
CHA2DS2-VASc scale in comparison to the CHADS2 scale, and to test the 
new oral anticoagulant recommendations in a sample of patients with AF 
recruited from primary care and cardiology outpatient clinics. 
 
 To assess the prevalence of AF as first clinical manifestation in patients with 
Brugada Syndrome, their demographic, clinical characteristics and diagnosis 
management in a large cohort of patients collected in a reference hospital in 
the field of the Brugada Syndrome. 
 
 To determine whether left bundle-branch block associated with AF has an 
independent, cumulative effect on mortality for patients without congestive 
heart failure. 
 
 To assess and compare the effect of digoxin on clinical outcomes in patients 
with AF versus those under beta-blokers or none, in patients with and 





 To determine the long-term effectiveness of hybrid therapy in the control of 
AF as well as the differences in clinical outcomes between patients with 
antiarrhythmic drug AFI, those with coexistent AFl and AF, and isolated AFl. 
 
 To assess the outcomes in terms of pacemaker implantation and potential 













































Rev Port Cardiol. 2013;32(2):103--109
Revista Portuguesa de
Cardiologia
Portuguese Journal of  Cardiology
www.revportcardiol.org
SPECIAL ARTICLE
Trends  in  clinical profile  and medical  treatments of  atrial
fibrillation patients  over the last 10 years
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Aim: We sought  to  define  trends  in AF  prevalence  and  its  medical  management  using  recent
data  based  on  data from  two  cross-sectional  studies  performed  in  a European  country  in  1999
and  2009.
Methods:  CARDIOTENS  1999  and  CARDIOTENS  2009  were  two observational,  cross-sectional,
multicenter studies.  Patients  were  recruited  in  from  primary  care  and  cardiology  outpatient
clinics.  A  total  of 32  051  and  25 137  subjects  were  analyzed  in  the  two  studies,  1540  and  1524
of  them,  respectively,  diagnosed  with  AF.
Results:  Over  the  course  of the  study  period  there  was  an  increase  in  the  prevalence  of AF
(from 4.8%  to  6.1%),  mainly  due  to  the  higher  prevalence  of  AF  in  patients  aged  over  70  years
(24.7%  vs.  37.1%).  Furthermore,  patients  with  AF  had  a higher  prevalence  of hypertension
(64.9% vs.  87.0%),  diabetes  (19.0%  vs. 37.4%),  heart  failure  (30.8%  vs.  34.8%),  coronary  artery
disease  (23.0%  vs.  25.8%)  and  previous  stroke  (1.5%  vs.  8.9%).  An  overall  increase  in  prescrip-
tion  of  antithrombotic/antiplatelet  therapy  was  observed  (33.0%  vs.  62.7%  and  31.0%  vs.  38.2%
respectively);  the  difference  observed  in  1999  between  prescription  of  oral  anticoagulation
by general  practitioners  and cardiologists  was  not  seen  in  the  later  study.  Differences  in  pre-
scription of  angiotensin-converting  enzyme  inhibitors  (28.0%  vs.  40.7%),  angiotensin  receptor
blockers  (10.0%  vs.  40.0%),  beta-blockers  (14.0%  vs.  41.5%)  and  calcium  channel  blockers  (21.0%
vs.  34.9%)  were  also  identified.
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Conclusions:  The  number  of  patients  with  AF  and  a higher  risk  for  thromboembolic  events
increased over  the  last  10 years.  More  aggressive  antithrombotic  treatment  has  been  observed,
especially  in  older patients.




Fatores  de  risco;
Anticoagulação oral;
Terapias de  upstream
Tendências  no  perfil  clínico  e  tratamentos  médicos  em  doentes  com fibrilhação
auricular  na  última  década
Resumo
Objetivos:  Procuramos  definir  as  tendências  prevalentes  de  fibrilhação auricular  (FA)  e o  trata-
mento médico  utilizando  dados  recentes,  colhidos  de  dois  estudos  transversais  realizados  num
país  europeu  entre  1999  e 2009.
Métodos: CARDIOTENS  1999  e  CARDIOTENS  2009  são  dois  estudos  observacionais,  transversais
multicêntricos. Os  pacientes  foram  recrutados  de  clínicas  de  ambulatório  dirigidas  por  gener-
alistas  e cardiologistas.  Um  total  de  32 051  e de  25  137  indivíduos  foram  analizados;  1  540  e  1
524  dos  quais  foram  diagnosticados  com  FA.
Resultados:  Durante  a realização do  nosso  estudo  houve  um  aumento  na incidência  de  FA (de
4,8% a 61,%)  sobretudo  devido  à elevada  prevalência  de  FA  em  pacientes  com  mais  de  70 anos
de  idade  (24,7%  versus  37,1%).  Para  além  disso  doentes  com  FA revelam  mais  tendência  para
hipertensão  (64,9%  versus  87,0%),  diabetes  mellitus  (19,0%  versus  37,4%),  insuficiência  cardíaca
(30,8%  versus  34,8%),  doença coronária  (23%  versus  25,8%)  e  acidente  vascular  cerebral  prévio
(1,5% versus  8,9%).  No  que  se  refere  a  terapia  antitrombótica/antiplaquetária,  foi observado
um  aumento  generalizado  na  sua prescrição (33,0%  versus  62,7%  e 31,0%  versus  38,2%  respeti-
vamente).  Sobre  este  assunto,  a diferença de  prescrição de  anticoagulantes  orais  observada  em
1999  entre  os  generalistas  e cardiologistas  não  se  verifica  atualmente.  Diferenças nos  agentes
inibidores  da  enzima  de  conversão  da angiotensina  (28,0%  versus  40,7%),  bloqueadores  recetores
da  angiotensina  (10,0%  versus  40,0%),  beta-bloqueantes  (14,0%  versus  41,5%)  e bloqueadores
dos canais  de  cálcio  (21,0%  versus  34,9%)  foram  igualmente  identificadas.
Conclusões: O  número  de  pacientes  com  FA  e eventos  trombo-embólicos  com  risco  mais  ele-
vado aumentou  ao  longo  da última  década.  Um  tratamento  antitrombótico  mais  agressivo  foi
observado  sobretudo  na população mais  idosa.
©  2012  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos  reservados.
Introduction
Atrial  fibrillation  (AF)  is  the most  common  sustained  car-
diac arrhythmia  in  clinical  practice.1,2 What  was defined  in
the past  as  a  simple  arrhythmia  characterized  by  irregu-
larly irregular  heartbeats  is  now accepted  as  a common  and
rapidly growing  clinical  problem  and as a disease  entity.  Few
previous studies  have reported  trends  in  the  prevalence3--5
and  medical  management  of AF  in  the  last 10 years  in a  Euro-
pean country,  specifically  regarding  oral  anticoagulation,
which should  reflect  the recommendations  of the European
guidelines.
Against this  background,  we  sought  to  define  trends  in  AF
prevalence and  its medical  management  based  on data  from
two cross-sectional  studies performed  in  a  European  country
at an  interval  of  10 years  (1999 and  2009).
Methods
Study  design
CARDIOTENS  19996 and CARDIOTENS  20097 were  two  obser-
vational, cross-sectional,  multicenter  studies  designed  by
the  Hypertension  Section  of  the  Spanish Society  of Cardiol-
ogy with  the aim  of describing  the  prevalence  and degree  of
control of  hypertension  and other  cardiovascular  risk factors
in Spain.  Both  studies recruited  patients  from  primary  care
and cardiology  outpatient  clinics.  Inclusion  criteria  were  age
≥18  years,  availability  of  clinical  records  and previous  car-
diovascular diagnoses,  and provision  of  written  informed
consent. Exclusion  criteria  were  illegal drug use  and refusal
to give  informed  consent.  A  total  of  1159  physicians  were
selected  in  the  CARDIOTENS  1999  study  and 885  in CAR-
DIOTENS 2009  (79.0%  and 89.1%  were general practitioners
and 21.0% and 10.9%  cardiologists,  respectively).  In  CAR-
DIOTENS 1999  all outpatients  were  seen  on the same  day  in
both primary  care  and  cardiology  settings.  In  CARDIOTENS
2009, every  physician  recruited  the  first  six patients  on five
consecutive days.  A  total  of  32  051  and  25  137  subjects  con-
stituted the  final  sample  of  each  registry;  1540  and 1524,
respectively, had  a current  or  previous  history  of  AF  and
entered this  substudy.
Definition  of variables
A  patient  was  identified  as having  AF if the records  included
either a  medical  report  or an electrocardiogram  confirming
Document downloaded from http://http://www.elsevier.pt, day 28/07/2013. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
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aHeart Rhythm Management Centre, University Hospital Brussels-UZ Brussels, Belgium
bDepartamento de Cardiologı́a, Hospital Universitario de San Juan, Sant Joan d’Alacant, Alicante, Spain
cDepartamento de Cardiologı́a, Hospital Complejo Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
dDepartamento de Cardiologı́a, Hospital Provincial de Castellón, Castellón de la Plana, Spain
eDepartamento de Cardiologı́a, Hospital Arnau de Vilanova, Lleida, Spain
fDepartamento de Cardiologı́a, Hospital de Galdakano, Vizcaya, Spain
gDepartamento de Cardiologı́a, Hospital Universitario Vall d’Hebron, Barcelona, Spain
Rev Esp Cardiol. 2011;64(8):649–653
Article history:
Received 11 December 2010
Accepted 7 March 2011





A B S T R A C T
Introduction and objectives: The guidelines for the management of atrial fibrillation (AF) incorporate new
risk factors for thromboembolism, trying to de-emphasize the use of the ‘low’, ‘moderate’, and ‘high’ risk
categories. The objective of this study was to determine the impact of the new scheme CHA2DS2-VASc
and of the new recommendations for oral anticoagulation (OAC) in a contemporary sample of patients
with AF seen by primary physicians and cardiologists.
Methods: Multicenter, observational, cross-sectional study on the epidemiology of hypertension and its
control, designed by the arterial hypertension department. Each researcher enrolled the first
6 consenting patients who came for examination during a 5-day period.
Results: Of 25 137 individuals recruited, 1544 were diagnosed with AF. The vast majority of the sample
had a CHADS2 score!2 (77.3%). Individuals with a risk score lower than 2 were categorized according to
the CHA2DS2-VASc score: 14.4% were aged 75 years or older (CHA2DS2-VASc = 2). Of those younger than
75, 42.3% had a CHA2DS2-VASc = 2; 23.7% CHA2DS2-VASc = 3, and 1.1% CHA2DS2-VASc = 4. This means
that the 85.1% of the patients with a CHADS2 score < 2 and no contraindications are indicated for OAC.
Conclusions: The new recommendations will result in a significant increase in patients with indications
for OAC, at the expense of those previously characterized as low-to-moderate risk. Therefore, patients at
risk of thromboembolic eventsmust be identified, although an evaluation of bleeding risk should be part
of the patient assessment before starting anticoagulation.
! 2011 Sociedad Española de Cardiologı́a. Published by Elsevier España, S.L. All rights reserved.






R E S U M E N
Introducción y objetivos: Las guı́as de fibrilación auricular (FA) de la Sociedad Europea de Cardiologı́a
incluyen en la estratificación del riesgo tromboembólico nuevos factores «moduladores» que recalifican
a un porcentaje de pacientes anteriormente catalogados de riesgo «bajo» o «moderado» a categorı́as
superiores. El objetivo de nuestro estudio es analizar el impacto de la escala CHA2DS2-VASc y las nuevas
recomendaciones de anticoagulación oral (ACO) en una muestra contemporánea de pacientes con FA
reclutados en consultas externas de cardiologı́a y atención primaria.
Métodos: Estudio epidemiológico observacional, transversal y multicéntrico diseñado por la sección de
hipertensión arterial con el objetivo de conocer la prevalencia y el control de la hipertensión en la
práctica clı́nica habitual. Cadamédico debı́a incluir a los primeros 6 pacientes de cada dı́a durante 5 dı́as.
Resultados: Se reclutó a 25.137 pacientes, de los que 1.544 tenı́an el antecedente de FA. De estos, el 77,3%
tenı́a una puntuación CHADS2! 2. Se recalificó según la escala CHA2DS2-VASc a la población restante con
CHADS2< 2. El 14,4% tenı́a ! 75 años (CHA2DS2-VASc = 2). De los menores de 75 años, el 42,3% tenı́a un
CHA2DS2-VASc = 2; el 23,7%, CHA2DS2-VASc = 3 y el 1,1%, CHA2DS2-VASc = 4. Esto supone que el 85,1% de
los pacientes con CHADS2 < 2 tendrán, en ausencia de contraindicaciones, indicación de ACO.
Conclusiones: Las nuevas indicaciones supondrán un incremento significativo en el número de pacientes
con indicación de ACO, a expensas de los previamente categorizados como con riesgo «bajo-moderado».
SEE RELATED ARTICLE:
DOI: 10.1016/j.rec.2011.04.004, Rev Esp Cardiol. 2011;64:639–41.
* Corresponding author: Heart Rhythm Management Centre, University Hospital Brussels-UZ Brussels, Laarbeeklaan 101, BE-1090 Brussels, Belgium.
E-mail address: mrodrigu@uzbrussel.be (M. Rodrı́guez-Mañero).
1885-5857/$ – see front matter ! 2011 Sociedad Española de Cardiologı́a. Published by Elsevier España, S.L. All rights reserved.
doi:10.1016/j.rec.2011.03.013
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Prevalence, Clinical Characteristics and Management of Atrial
Fibrillation in Patients With Brugada Syndrome
Moisés Rodríguez-Mañero, MD*,†, Mehdi Namdar, MD†, Andrea Sarkozy, MD, PhD,
Rubén Casado-Arroyo, MD, Danilo Ricciardi, MD, Carlo de Asmundis, MD, PhD,
Gian-Battista Chierchia, MD, Kristel Wauters, MD, Jayakeerthi Y. Rao, MD,
Fatih Bayrak, MD, Sophie Van Malderen, MD, and Pedro Brugada, MD, PhD
Atrial fibrillation (AF) can be the first manifestation of latent Brugada syndrome (BS). The
aim of our study was to assess the prevalence of AF as the first clinical diagnosis in patients
with BS and their demographic and clinical characteristics and diagnosis management in
a large cohort of patients. The patient group consisted of 611 patients with BS. The data from
those with a diagnosis of AF previous to the identification of BS were analyzed (n [ 35).
Eleven cases were unmasked after the initiation of a class I antiarrhythmic drug and one
during the establishment of general anesthesia. In the remaining population, BS was diag-
nosed using an ajmaline test performed mainly because of younger age in patients with lone
AF (n[ 13), previous syncope or sudden cardiac death (n[ 3), or a clinical history of sudden
cardiac death in the family (n [ 5). The mean patient age was 49 – 15 years, 21 were male
patients, 14 had a family history of sudden death, 15 had had previous syncope, and 4 had
survived cardiac arrest. Concomitant electrical disorder was found in 13 patients. Remark-
ably, 21 patients had normal findings on the baseline electrocardiogram. In conclusion, AF
could be one of the first clinical manifestations of latent BS in a considerable number of
patients. This identification is crucial because the treatment of these patients is subject to
relevant changes. The ajmaline test plays an essential role, mainly in young patients with
a family history of sudden death, despite having normal findings on a baseline electro-
cardiogram. ! 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:362e367)
Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia, occurring in 1% to 2% of the general
population.1 The main risk factors for the development of
AF are arterial hypertension and structural heart disease.
Nevertheless, "30% of patients with AF can have “lone
AF,”1 which can be, in certain cases, of hereditary origin.2
Accordingly, during previous years, numerous inherited
cardiac syndromes associated with AF have been identified,
including Brugada syndrome (BS).3,4 Moreover, AF can
even be the first manifestation of latent BS.5 This has crucial
importance in terms of medical management, in particular,
because of the contraindication for a series of antiarrhythmic
and other drugs.6 The aim of our study was to assess the
prevalence of the diagnosis of AF previous to the identifi-
cation of BS in a large cohort of patients. We also reviewed
their demographic and clinical characteristics.
Methods
A total of 611 patients with the BS were included in our
database from 1995 to 2011. Of these, we analyzed the data
from those who had documented AF (defined as !1 docu-
mented episode of paroxysmal AF lasting >30 seconds)
previous to the diagnosis of BS. Lone AF was defined as AF
occurring in the absence of structural heart disease, a history
of hypertension, and/or left ventricular hypertrophy, as
determined by physical examination, electrocardiography,
chest radiography, and echocardiography. The diagnosis of
BS was determined using the recommendations of the
Brugada consensus reports,7,8 with recent modifications.9,10
Accordingly, in the assessment of a potential conversion to
a typical type 1 Brugada electrocardiographic pattern,
patients with types 2 and 3 Brugada electrocardiographic
patterns underwent pharmacologic testing with intravenous
ajmaline at a dose of 1 mg/kg body weight as a continuous
infusion within 5 minutes. The test was performed with
continuous electrocardiographic recording, and, after
administration of the last dose, the electrocardiographic
recording was continued for another 10 minutes. The
ajmaline test findings were considered positive if a normal
or type 2 or 3 electrocardiographic pattern converted to
a coved-type electrocardiographic pattern with an ST-
segment elevation of >0.2 mV in !1 right precordial lead,
including recordings from the third intercostal space. The
PR, QRS, and QTc intervals were measured before and after
the test in all patients.
The occurrence of sudden cardiac death (SCD) in the
family was categorized as follows: <35, 35 to 55, and 56 to
65 years old. An electrophysiologic study was performed in
asymptomatic patients to perform risk stratification and in
the symptomatic patients (those with syncope, previous
Heart Rhythm Management Center, Universitair Ziekenhuis Brussels e
Vrije Universiteit Brussel, Brussels, Belgium. Manuscript received July 26,
2012; revised manuscript received and accepted October 2, 2012.
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Doble respuesta nodal incesante y fibrilación auricular paroxı́stica
Incessant Double Ventricular Response and Paroxysmal Atrial Fibrillation
Moisés Rodrı́guez-Mañero*, Alfonso Macı́as Gallego e Ignacio Garcı́a Bolao
Departamento de Cardiologı́a, Unidad de Arritmias, Clı́nica Universidad de Navarra, Pamplona, Navarra, España
La fibrilación auricular puede desencadenarse por ritmos auriculares rápidos, entre ellos la taquicardia intranodal. Se presentan los
registros de un paciente diagnosticado de fibrilación auricular paroxı́stica y remitido para ablación de venas pulmonares tras el fracaso de
distintos fármacos antiarrı́tmicos (bisoprolol, flecainida y amiodarona). En el estudio inicial, la observación de dos complejos QRS con una
sola onda p hizo sospechar la presencia de doble vı́a nodal, como posteriormente se comprobó, y cambiar la estrategia terapéutica. Este
fenómeno es una manifestación electrofisiológica de la doble vı́a nodal, pero se trata de un hallazgo infrecuente debido a que requiere gran
diferencia en los tiempos de conducción entre ambas vı́as.
El electrocardiograma (ECG) basal (fig. 1) se interpretó como bigeminismo supraventricular; sin embargo, el estudio electrofisiológico
mostró que realmente se trataba de doble respuesta nodal repetitiva espontánea, que desencadenaba rachas de taquicardia (fig. 2A) y
fibrilación auricular. La activación auricular se conduce por ambas vı́as nodales simultáneamente, pero con distintas velocidades de
conducción (fig. 2B), en ocasiones con posterior conducción retrógrada por la vı́a rápida, que la perpetuaba (figs. 2A y C, y 3). Tras la ablación
de la vı́a lenta nodal, desaparecieron la doble respuesta y las rachas de taquicardia (fig. 2D) y se puso de manifiesto un patrón de conducción
AV y VA continuo y decremental.
En el seguimiento, el paciente permaneció asintomático, sin tratamiento antiarrı́tmico y en ritmo sinusal estable, sin recidiva
documentada en el Holter-ECG a los 3, 6 y 12 meses.
Rev Esp Cardiol. 2012;65(7):668
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Left bundle branch block in atrial fibrillation patients without heart failure
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Left bundle branch block
Previous studies have shown that left bundle branch block (LBBB)
is associated with an increase in all-cause mortality in patients with
congestive heart failure (HF) [1], but also it has been reported that QRS
duration was associated with an adverse outcome in HF patients with
preserved left ventricle ejection fraction (LVEF) [2]. Whether a complete
LBBB can predict risk remains to be established and at the present time
no prospective studies have been done in patients with atrial fibrillation
(AF) and not HF nor left ventricular dysfunction. These raise the
question if a more aggressive therapeutic strategy or closer clinical
follow-up should be considered in AF patients with LBBB and normal
LVEF nor symptoms of HF.
Based on the AFBAR study (Atrial Fibrillation in the BARbanza area, a
prospective study that has been previously described in detail [3–5],
n = 777 patients) we aimed to assess and compare in a prospectiveway
the effect of LBBB on clinical outcomes in patients with AF and no HF nor
LV dysfunction. LBBB was classified according to the Minnesota Code
criteria for complete LBBB (Minnesota Code 7.1) [6]. Outcomes
considered in the present investigation were survival, morbidity
(survival free of admission due to any cause) and cardiovascular
morbidity (survival free of admission due to cardiovascular cause). For
this purpose, two categories were done: patients without LBBB (group
Abbreviations: AF, Atrial fibrillation; ARB, Angiotensin-receptor blocker; ACEI,
Angiotensin-converting enzyme inhibitor; HF, Heart failure; LBBB, Left bundle-branch
block; LVEF, Left ventricular ejection fraction; LVH, Left ventricular hypertrophy.
⁎ Corresponding author at: Hospital Clínico Universitario, Santiago de Compostela
Spain, Travesía da Choupana, SN, Spain. Tel.: +34 616 90 32 75.
E-mail address: moirmanero@gmail.com (M. Rodríguez-Mañero).
1 Both authors contributed equally to the elaboration of this manuscript.
Table 1
Baseline characteristics of study population.
LBBB (n = 67) Not LBBB (n = 697) P
Age (years) 76.63 (8.1) 74.50 (9.3) 0.04
AF duration (years) 6.97 (5.3) 6.05 (5.2) 0.1
Male (%) 12.1/8.5 87.9/91.5 0.1; 0.1
Creatinine clearance (mg/dl) 62.5 (25.3) 66.94 (24.9) 0.1
Hg glycosylated (%) 6.92 (1.6) 6.75 (1.4) 0.6
BMI 29.8 (5.1) 30.1 (4.7) 0.5
Abdominal circumference (cm) 101.13 (14.4) 100.2 (11.9) 0.5
Hypertension (%) 83.6 75.9 0.1
Diabetes mellitus (%) 31.3 23.6 0.1
Ischemic cardiopathy (%) 22.4 17.0 0.2
Heart failure (%) 0 11.8 0.03
Prosthesis (%) 3.0 3.4 0.8
Valvulopathy (%) 29.2 32.2 0.6
COPD (%) 22.4 17.5 0.3
Stroke (%) 1.5 4.7 0.2
LVEF (%) 55.7 (12.1) 60.7 (11.5) 0.04
Renal insufficiency (%) 19.4 8.3 0.03
≥3 risk factors (%) 65.7 68.0 0.7
Antiplatelets (%) 17.9 18.2 0.9
Digoxine (%) 31.3 31.6 0.9
Beta blockers (%) 37.3 29.8 0.2
IECAS (%) 43.3 29.8 0.02
ARAII (%) 41.8 37.6 0.5
Antialdosteronic (%) 6.0 6.5 0.8
Statins (%) 50.7 48.9 0.7
Abbreviations: AF: atrial fibrillation; ARB: angiotensin-receptor blocker; BMI: body
mass index; ACEI: angiotensin-converting enzyme inhibitor; COPD: chronic obstructive
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A B S T R A C T
Introduction and objectives: We aimed to assess and compare the effect of digoxin on clinical outcomes in
patients with atrial fibrillation vs those under beta-blockers or none of these drugs.
Methods: AFBAR is a prospective registry study carried out by a team of primary care physicians
(n = 777 patients). Primary endpoints were survival, survival free of admission due to any cause, and
survival free of admission due to cardiovascular causes. The mean follow up was 2.9 years. Four groups
were analyzed: patients receiving digoxin, beta-blockers, or digoxin plus beta-blockers, and patients
receiving none of these drugs.
Results: Overall, 212 patients (27.28%) received digoxin as the only heart control strategy, 184 received
beta-blockers (23.68%), 58 (7.46%) were administered both, and 323 (41.57%) received none of these drugs.
Digoxin was not associated with all-cause mortality (estimated hazard ratio = 1.42; 95% confidence
interval, 0.77-2.60; P = .2), admission due to any cause (estimated hazard ratio = 1.03; 95%
confidence interval, 0.710-1.498; P = .8), or admission due to cardiovascular causes (estimated hazard
ratio = 1.193; 95% confidence interval, 0.725-1.965; P = .4). No association was found between digoxin use
and all-cause mortality, admission due to any cause, or admission due to cardiovascular causes in patients
without heart failure. There was no interaction between digoxin use and sex in all-cause mortality or in
survival free of admission due to any cause. However, an association was found between sex and admission
due to cardiovascular causes.
Conclusions: Digoxin was not associated with increased all-cause mortality, survival free of admission
due to any cause, or admission due to cardiovascular causes, regardless of underlying heart failure.
! 2014 Sociedad Española de Cardiologı́a. Published by Elsevier España, S.L.U. All rights reserved.
Seguimiento clı́nico de una muestra contemporánea de pacientes con fibrilación





R E S U M E N
Introducción y objetivos: Evaluar el efecto de la digoxina en los resultados clı́nicos de los pacientes con
fibrilación auricular con y sin tratamiento con bloqueadores beta.
Métodos: El AFBAR es un registro prospectivo llevado a cabo por un equipo de médicos de atención
primaria (n = 777 pacientes). Los objetivos principales fueron la supervivencia, la supervivencia libre de
hospitalización por cualquier causa y la supervivencia libre de hospitalización por causas
cardiovasculares. La media de seguimiento fue 2,9 años. Se analizaron cuatro grupos: pacientes
tratados con digoxina, bloqueadores beta o digoxina más bloqueadores beta, y pacientes que no recibı́an
ninguno de estos fármacos.
Resultados: En total, 212 pacientes (27,28%) recibieron digoxina como única estrategia de control de
frecuencia; 184 recibieron bloqueadores beta (23,68%); 58 (7,46%), ambos fármacos y 323 (41,57%),
ninguno de ellos. El tratamiento con digoxina no se asoció a la mortalidad por todas las causas (razón de
riesgos estimada = 1,42; intervalo de confianza del 95%, 0,77-2,60; p = 0,2), la hospitalización por todas
las causas (razón de riesgos estimada = 1,03; intervalo de confianza del 95%, 0,710-1,498; p = 0,8) ni la
hospitalización por causas cardiovasculares (razón de riesgos estimada = 1,193; intervalo de confianza
* Corresponding author: Servizo de Cardioloxı́a, Hospital Clı́nico Universitario, Travesı́a da Choupana s/n, 15706 Santiago de Compostela, A Coruña, Spain.
E-mail address: moirmanero@gmail.com (M. Rodrı́guez-Mañero).
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Objectives: To determine the long-term effectiveness of hybrid therapy in the control of atrial fibrillation (AF) as
well as the differences in clinical outcomes between patients with antiarrhythmic drug atrial flutter (AAD-AFl),
those with coexistent AFl and AF, and isolated AFl.
Methods: Four hundred eight patients who consecutively underwent cavotricuspid isthmus (CTI) ablation be-
tween 1998 and 2010 were followed for 5.9 years. Twenty-seven patients had AAD-AF1 (Group 1): they had
AF but not AFl at baseline but on AAD therapy they showed typical AFl. They underwent CTI ablation and contin-
ued with AAD therapy, 96 patients had coexistent AF1 and AF at baseline (Group 2) and continued with AAD
therapy at the discretion of their cardiologists and 284 patients had isolated AFl (Group 3).
Results: AF recurred in the majority of the AAD-AF1 patients (74%, incident density rate (IDR): 19.1/100 person-
years). This incidence rate was similar to the recurrence rate of AF in patients with coexistent AFl and AF (59%,
IDR: 19.2/100 person-years). The patients in Group 1 had a similar IDR of stroke as Group 2 and a slightly higher
rate than Group 3. There were no significant differences in the IDR for death among Groups 1, 2 and 3.
Conclusions: Hybrid therapy was not effective for long-term control of AF. The clinical outcomes (AF, stroke and
death) were similar for AAD-AF1 patients and patients with coexistent AF and AFl.
© 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
The coexistence of atrial fibrillation (AF) and atrial flutter (AFl) is a
well-recognized and commonly encountered occurrence in the clinical
setting [1,2] AF was first observed to spontaneously organize into AFl
by Garrey in 1924 [3]. More recently, it has been shown that antiar-
rhythmic drugs (AAD) can organize AF into AFl [4]. Furthermore, animal
models have demonstrated that this organization occurs when the
fibrillatory wave front encounters a functional line of block in the
right atrium. Unidirectional conduction block of the wave front causes
thewave to turn around the area of functional block and return through
an area of slow conduction, thereby creating a re-entrant circuit [5]. The
administration of AAD to patients with AF allows for the formation of
these lines of functional block and hence organization into AFl.
Hybrid therapy is a management strategy that consists of the
ablation of cavotricuspid isthmus (CTI) and continued pharmacologic
therapy when treatment with Class I or III AAD organizes AF into AFl.
Numerous studies have shown hybrid therapy to be an effective treat-
ment with AF recurrences rates ranging between 11 and 27% [6–8].
However, these studies have been limited by short follow-up periods.
In the present study, we aimed to evaluate AF recurrence, stroke and
death during long-term follow-up in a cohort of patients with AF to
AF1 conversion following treatment with AAD (AAD-AFl) compared
with patients with coexisting AF and AFl after radiofrequency catheter
ablation of CTI.
2. Methods
2.1. Baseline population characteristics
Four hundred and eight consecutive patients with typical AFl who successfully
underwent radiofrequency catheter ablation at our hospital between November 1998
International Journal of Cardiology 176 (2014) 74–79
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Introduction: Little is known about the risk of pacemaker implantation after common atrial flutter ablation in the
long-term.
Methods: We retrospectively reviewed the electrophysiology laboratory database at two Spanish University
Hospitals from 1998 to 2012 to identify patientswhohad undergone successful ablation for cavotricuspid depen-
dent atrial flutter. Cox regression analysis was used to examine the risk of pacemaker implantation.
Results: A total of 298 patients were considered eligible for inclusion. The mean age of the enrolled patients was
65.7± 11. During 57.7 ± 42.8 months, 30 patients (10.1%) underwent pacemaker implantation. In the stepwise
multivariate models only heart rate at the time of the ablation (OR: 0.96; 95% CI: 0.93–0.98; p b 0.0001) and in-
traventricular conduction disturbances in the baseline ECG (OR: 3.87; 95% CI: 1.54–9.70; p = 0.004) were inde-
pendents predictors of the need of pacemaker implantation. A heart rate of ≤65 bpm was identified as the
optimal cut-off value to predict the need of pacemaker implantation in the follow-up (sensitivity: 79%, specific-
ity: 74%) by ROC curve analyses.
Conclusion: This is the first study of an association between the slow conducting common atrial flutter and sub-
sequent risk of pacemaker implantation. In light of these findings, assessing it prior to ablation can be helpful for
the risk stratification of sinus node disease or atrioventricular conduction disease requiring a pacemaker implan-
tation in patients with persistent atrial flutter.
© 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Typical atrial flutter (AFL) is a common arrhythmia, representing
about 10% of hospitalizations for supraventricular tachycardia in adults
[1]. The reentrant circuit through the isthmus cavotricuspid (CTI) is lo-
cated in the right atrium and the left atrium is then activated passively
[2]. Therefore, radiofrequency (RF) ablation of atrial flutter appears as
a reasonable approach regarding feasibility and effectiveness, and it is
considered as a low procedural risk [3–7]. Most studies on ablation-
related complications concern all indications of ablation, however, little
is known about the risk of pacemaker implantation (PMI) after un-
eventful successful CTI ablation in the long term follow-up [8–10].
The purpose of the studywas to assess the outcomes in terms of PMI
and potential predictors after uneventful successful RF ablation proce-
dure of typical AFL.
2. Methods
We retrospectively reviewed the electrophysiology laboratory database at two
Spanish University Hospitals from 1998 to 2012 to identify patients who had undergone
electrophysiology (EP) study for CTI dependent AFL. Eligible criteria included the follow-
ing: (i) CTI participation in the arrhythmic circuit confirmed by an EP study, (ii) an atrial
activation pattern during atrial tachycardia (AT) showing a clockwise or counterclockwise
rotation around the tricuspid annulus (TA), (iii) termination of the AFL by a CTI linear ab-
lation, and (iv) atrial flutter persisting for more than 2 weeks. Typical AFL was diagnosed
when the surface ECG showed flutter waves thatwere pre-dominantly negative in leads II
and III, and aVF and positive in lead V1, with a regular atrial rate [1]. However, patients
with atypical flutter waves were not included in our study. Also, patients were excluded
if they had previously undergone an AFL ablation or PMI for sinus node dysfunction dis-
ease (SND) or auriculoventricular (AV) conduction disease. Finally, patients who
presented complete AVB occurring during ablation of atrial flutter by an inadvertent
application of energy on the normal AV conduction system were excluded.
Ablation of AFL by RF was performed by the conventional method using a “HALO”
catheter. Energy was delivered by a RF catheter 8 mm to use a maximum power of
70 W and a maximum target temperature of 60°. PR interval was registered in the entire
International Journal of Cardiology 202 (2016) 285–288
Abbreviations: AFL, atrial flutter; CTI, cavotricuspid isthmus; EPS, electrophysiology
study; HR, heart rate; PMI, pacemaker implantation; RF, radiofrequency.
⁎ Corresponding author at: Division of Cardiac Electrophysiology, Department of
Cardiology, Clinic University Hospital of Santiago de Compostela, Travesía da Choupana
SN, Santiago de Compostela (Spain).
E-mail address: moirmanero@gmail.com (M. Rodríguez-Mañero).
1 Both authors contributed equally to the elaboration of this manuscript.
http://dx.doi.org/10.1016/j.ijcard.2015.08.210
0167-5273/© 2015 Elsevier Ireland Ltd. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Cardiology
































Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical 
practice1,2. What was defined in the past as a simple arrhythmia characterized 
by irregularly irregular heartbeats is now accepted as a common and rapidly 
growing clinical problem and as a disease entity. As a matter of fact, it has 
generated a wide range of research in the last years, particularly in the last two 
decades. Nevertheless, as we have tried to reflect through the course of this 
thesis, there are still lots of doubts that deserve further investigation. We have 
stopped in some points.  
First of all, based on the CARDIOTENS study, we have focused in the 
epidemiology, treatment and risk profile of patients with AF at the current 
moment and the trend in the last decade, showing that not only AF prevalence 
has increased but also, the current AF population exhibits a higher risk profile 
for thromboembolic events, leding to radical changes in the use of oral 
anticoagulants and emphasis on upstream therapies.  
Secondly we have tried to define the impact of the new scheme (CHA2DS2-
VASc) in a contemporary sample of patients with AF. As we have hypothesized, 
these new indications will imply a significant increase in the number of patients 
with indications for this type of therapy, at the expense of those previously 
categorized as low-to-moderate risk. 
Thirdly, based on in-hospital data, we have shown that “lone AF” is not always 
“lone”, and could be the first manifestation of a latent Brugada Syndrome. 






node, can simulate or trigger an AF episode, reason why a brief case report has 
been included in order to emphasys this point.  
Fourthly, grounded on the AFBAR study, we have tried to determine whether 
LBBB associated with AF had an independent, cumulative effect on mortality for 
patients without congestive heart failure, in order to assess if a more aggressive 
therapeutic strategy or closer clinical follow-up should be recommended in this 
setting. Despite our hypotesys, lack or relationship between LBBB and 
mortality-morbility has been shown and up until today routinely follow up can be 
safely recommended in these patients.  
Based also on the AFBAR population, we have tried to assess the effect of 
digoxin on clinical outcomes in patients with AF. Digoxin was not associated 
with increased all-cause mortality, survival free of admission due to any cause 
and due to cardiovascular cause, regardless of sex and presence or absence of 
underlying heart failure.  
Unending with the medical treatament of patients with AF we have addressed 
the rate of AF recurrence, stroke and death during long-term follow-up in a 
cohort of patients with AF to AFI conversion following treatment with AAD (AAD-
AFl) compared with patients with coexisting AF and AFl after radiofrequency 
catheter ablation of CTI. From our point of view, since the coexistence of these 
two arrhythmias and the pathological mechanisms underlying them usually go 
hand-in-hand, evaluation of this so-called “hybrid therapy” (ablation of the CTI 
and continued pharmacologic therapy with Class I or III AAD) recommended by 




where radiofrequency ablation of AF and AFI represent a well-stablished 
strategy.  
Finally, in the last part of this thesis, we have focused on the outcomes in terms 
of PCM implantation and potential predictors after uneventful successful 
radiofrequency ablation procedure of typical AFI. This potential risk of 
auriculoventricular block with the subsequent need of PCM implantation has not 
been described up to date. However, from a clinical point of view this possibility 
is very relevant, and as shown before, baseline HR and ECG intraventricular 
conduction disturbance are simple clinical markers to be taken into account by 
the physician before and after a CTI ablation. For instance, to start with, these 
patients could require more cautious monitoring with special attention to the 
development of syncope, dizziness or dyspnoea. Secondly, it also should be 
taken into account at the time of the prescription of rate-control drugs that could 
impair sinus node function or AV conduction. 
Next, we will review in detail the most important ideas of the abovementioned 
studies: 
 
Trends in clinical profile and medical treatments of atrial fibrillation patients over 
the last 10 years 
Based on data obtained from the CARDIOTENS 1999 and CARDIOTENS 2009 
we have tried to define trends in AF prevalence and its medical management. 
We hypothesized that a radical change in the risk profile for thromboembolic 
events in patients with AF has ensued, as also a change in the use of oral 






the prevalence of AF was observed throught the course of the study. This 
increase was mainly due to a higher prevalence of AF in patients aged over 70. 
Interestingly, a more aggressive antithrombotic treatment and radical changes 
in the use of oral anticoagulants have also been noticed. Comparison of the two 
registries thus revealed significant shifts in the perception and treatment of 
patients with atrial fibrillation. We have tried to give some explantations to those 
results. One possible explanation for the increase in AF prevalence is that 
today’s elderly are a sicker population: advances in preventive medicine and 
increasing socioeconomic prosperity have resulted in a population of elderly 
survivors with a higher prevalence of comorbidities including hypertension, 
diabetes, heart failure, coronary artery disease and prior cardiac surgery, in 
comparison with their counterparts who lived to a similar age 50 years ago. 
Nonetheless, as we pointed out in the manuscript, when these risk factors are 
put into context with the size of the increase in AF prevalence, the relatively 
small increase in the prevalence of known comorbidities does not appear to 
offer more than a partial explanation, reason why it is our belief that there must 
be something else than simply ageing of the population1. Hence, these 
epidemiological studies need to be complemented with further analysis aimed at 
defining the molecular genetics of AF, in order to provide more insights into the 
structural and electrical phenotypes resulting from genetic mutations and their 
interactions with the environment. Otherwise, there is a danger that the burden 
of this disease could reach epidemic proportions in coming years. 
In the present study we have also pointed out that physicians should be aware 
that we are facing more complex patients, since the elderly have not only the 




bleeding. Moreover, the herein presented AF population exhibited a higher risk 
for thromboembolic events, due to the higher prevalence of hypertension, 
diabetes, previous stroke and heart failure. To our understanding these results 
are relevant since they indicate a need for new therapeutic strategies, including 
new oral anticoagulant agents. These agents, which must have a safer drug 
profile, may provide a useful alternative to current vitamin K antagonists. 
It is noteworthy in this study the fact that prevalence of hypertension in patients 
with AF has also increased in the last decade. Nevertheless, there has been 
progress in the rate of hypertension control (with a relative increase of 38.5%). 
This is important because of the emphasis on upstream therapies to slow or halt 
the progression of AF due to underlying cardiovascular disease and to atrial 
fibrillation itself. Such agents include ACEIs, ARBs, statins, n-3 (omega-3) 
polyunsaturated fatty acids, and possibly corticosteroids. As seen in this study, 
the recommendations reflect the evolution of medical therapeutics in the last 10 
years, with a significant increase in the prescription rate of beta-blockers, 
ACEIs/ARBs and statins. Significant changes were also observed in the choice 
of ventricular rate control agents throughout the study period. In the 1990s, 
digoxin was the preferred agent for controlling ventricular rate, but during the 
study period the use of beta-blockers and CCBs increased significantly, due in 
part to the growing recognition that digoxin is particularly ineffective at 
controlling ventricular rate with effort.  
To summarize, this comparative analysis of these two large observational, 
cross-sectional cohort studies has revealed long-term trends in the prevalence 







Impact of New Criteria for Anticoagulant Treatment in Atrial Fibrillation 
The second study presented here are the results derivated from the 
CARDIOTENS 2009. The objective of this study was to determine the impact of 
the new scheme CHA2DS2-VASc and the new recommendations for oral 
anticoagulation (OAC) in a contemporary sample of patients with AF seen by 
primary physicians and cardiologists. Our hypothesis was that this new 
approach would reclassifies a substantial number of patients previously 
considered ‘‘low’’ or ‘‘moderate’’ risk into higher categories, with the subsequent 
increase in the indication for OAC. The true magnitude of these 
recommendations had never been quantified. We found that the new 
recommendations will result in a significant increase in patients with indications 
for OAC, at the expense of those previously characterized as low-to-moderate 
risk. In this cohort, a couple of findings called our attention. Firstly was the fact 
that the large majority of the study population had a moderate-to-high risk 
profile for thromboembolic events (77.3% had a CHADS2 ≥2). However, in spite 
of this, a high percentage of high-risk patients (35%) were not taking 
anticoagulants. We postulated that contraindications for OAC could partially 
explain this situation, but also the lack of medical indication and patient 
compliance due to the need for close monitoring and/or fear of bleeding. Within 
this subgroup of patients at risk for thromboembolism without OAC therapy, the 
preferred strategy was monotherapy with acetylsalicylic acid, even though this 
treatment is less effective than OAC in reducing thromboembolism, both in 
monotherapy68 and together with clopidogrel50. Furthermore, this treatment also 
produces high rates of bleeding. Perhaps with new anticoagulant alternatives 




extent, thus increasing the use of OAC in patients for whom this therapy is 
indicated. 
This results are relevant since this strategy is supposed to lead a reduction in 
the risk of thromboembolic events, but also an increase in the overall number of 
bleeding events, reason why, now more than ever, it will be crucial to identify 
this at-risk population, minimizing hece the potential risks inherent to the 
anticoagulant therapy, especially in the elderly. The new clinical guidelines can 
also be of help in this regard, as they provide bleeding risk scales that must be 
taken into account. Current recommendations continue to leave the choice of 
prescribing OAC or antiplatelet therapy to the physician within a certain range of 
patients, specifically those with a CHA2DS2-VASc score of 1 (although OAC is 
recommended). In any case, this will be a much lower percentage of patients 
(1.8% in our registry) because many patients will have clear indications for 
anticoagulants in the absence of contraindications. 
In this study we sought to warrant that this new suggestions had not gone 
without detractors who believe that the recommendations set forth are too 
exhaustive, with no clear benefits demonstrated in randomized clinical trials for 
each specific scenario, and that the guidelines have been established without 
conclusive data supporting improved patient prognosis as compared to the 
previous CHADS2 scale. Although some markers are easy to define, such as 
age or sex, vascular disease represents a much more diffuse and 








Prevalence, Clinical Characteristics and Management of Atrial Fibrillation in 
Patients With Brugada Syndrome 
The third study herein discussed was based on a large cohort of patients with 
BS collected in a leading Hospital in this field. Taking advantage of the high 
volume, one of the biggest up today, we aimed to assess the prevalence of AF 
as the first clinical diagnosis in patients with BS and their demographic and 
clinical characteristics and diagnosis management in a large cohort of patients. 
Based on small series and previous case reports, we postulated that a relevat 
percentage of patients with BS would have AF as first clinical manifestation. 
Interestingly, this hypothesis was confirmed and we found that AF might be one 
of the first clinical manifestations of latent BS in a significant number of patients, 
suggesting that disregarding this association could have tragic consequences. 
Furthermore, we have tried to highlight the role of the ajmaline test as a useful 
tool in the diagnostic workup of patients with AF, especially in those with a 
family history of sudden cardiac death or syncope, regardless of the baseline 
electrocardiographic findings. 
In the study, we have attempted to find explanations to this association. First of 
all, the mutation in the cardiac sodium channel might exist, not only in 
ventricular but, most importantly, also in atrial myocytes85-86, which could be the 
substrate for reentrant atrial tachyarrhythmias and the increased atrial 
vulnerability observed in subjects with BS87. This could explain, in part, the 
association between AF and BS. Additionally, it is believed that vagal activity 
plays an important role in ST-segment elevation and the occurrence of 
ventricular fibrillation in patients with BS85; therefore, it is conceivable that this 




owing to the presence of a prominent cardiac transient outward potassium 
current in the atria and the observation that episodes of AF are triggered by 
closely coupled atrial extrasystoles, it has been postulated that a substrate 
similar to that responsible for ventricular arrhythmogenesis might underlie the 
development of AF in patients with BS88. 
To our understanding, these results are crucial since treatment of these patients 
is subject to relevant changes. First, the prescription of class 1C AADs could 
prove to be unsafe and should be avoided in these subjects owing to the 
increased risk of SCD. As a matter of fact, we reported in the abovementioned 
study, 2 patients with tragic consequences after the initiation of class 1C AADs. 
Second, identification of these subjects is of great importance due to the 
subsequent risk stratification of SCD, in line with the avoidance of drugs that 
could increase the risk of ventricular arrhythmias.   
In this study we also try to highlight the role of ajmaline or class IC AAD as a 
critical step in the diagnostic workup of concealed BS, mainly because it usage 
is not emphasized in the current European Society of Cardiology/American 
College of Cardiology/American Heart Association AF guidelines3. Our 
argument is that pathognomonic electrocardiographic changes in BS are 
dynamic and not reliably reproducible. In our study, 60% of the patients 
presented with an absolutely normal initial electrocardiogram. Thus, 
interrogation of the patient’s history is absolutely mandatory. In our series, 40% 
of the patients with AF as the first clinical manifestation of BS, had a positive 
family history of SCD and 42% had reported previous syncope. This suggests 
that, regardless of the baseline electrocardiographic findings, the suspicion 






and the family history, emphasizing the crucial importance of this easy-to-
assess and simple test for improved characterization of potentially affected 
patients. 
Concerning the so-called “pseudo lone AF”, we have also included a case 
report of a young male patient with paroxysmal AF referred for pulmonary vein 
isolation following failure of various AAD treatments. Importantly, the 
electrophysiologic study perfomed during the procedure, before the ablation, 
showed that it was actually a spontaneous repetitive double nodal response that 
triggered runs of tachycardia and AF. Following ablation of the slow nodal 
pathway, the double response and runs of tachycardia disappeared and during 
follow-up, the patient remained asymptomatic, with stable sinus rhythm and no 
antiarrhythmic treatment.  
In conclusion, in this section, we have tried to highlight that when facing with a 
patient with AF, a diagnostic work up must be performed in order to rule out 
potential causes beyond “pulmonare vein firing”, as for instance, BS or slow 
pathway mediated tachycardia. 
 
Left bundle branch block in atrial fibrillation patients without heart failure.  
Based on the AFBAR study (a prospective study carried out by a team of 
Primary Care physicians in a single health-service) we aimed to determine 
whether LBBB associated with AF had an independent, cumulative effect on 
mortality for patients without congestive heart failure in order to evaluate if a 
more aggressive therapeutic strategy or closer clinical follow-up should be 




than in patients without LBBB. Nevertheless, contrary to our hypothesis, after 
adjusting for potential confounders, LBBB was not predictive of all-cause death, 
admission to any cause or cardiovascular cause. 
At the time of the study, several series have reported the long-term follow up of 
patients with AF and rate control. However, little information was available 
regarding the outcome of AF patients without heart failure and 
electrocardiographic finding of LBBB. As a matter of fact, it was not specifically 
collected in the AFFIRM trial20. Data coming from the Framingham cohort 
showed that although QRS duration was not associated with major 
cardiovascular end points110, increased QRS duration was associated with an 
increase in all-cause mortality or cardiac death in patients with LV systolic 
dysfunction111. Recent studies further showed that a prolonged QRS duration 
was associated with an adverse outcome in HF patients with preserved LVEF 
and patients with sinus nodal dysfunction with or without HF112. Moreover, 
adverse outcomes in patients with preserved LV systolic function and a 
prolonged QRS seem to be more common than in systolic heart failure patients 
without QRS prolongation102. In the setting of patients with normal LVEF or 
those without HF symptoms, a retrospective study reported that progressive 
increase in QRS duration predicted a poor prognosis in AF patients with 
preserved LV function112. Kruger et al. reported that QRS duration and brain 
natriuretic peptide levels were independent predictors of LV systolic dysfunction 
in patients with sinus rhythm or AF113. Conversely, results from the AFBAR 
study did not show that LBBB was predictive of all-cause death. It also failed to 
show a predictive value for admission due to any cause and admission due to 






study addressing the rate of in hospital admission in patients with AF, LBBB and 
no signs of HF neither LV dysfunction. On the other hand, the etiology of LBBB 
in subjects without evidence of structural heart disease is usually an age-related 
degeneration of the conduction system, which may be either a focal (Lev’s 
disease)114 or a diffuse (Lenegre’s disease)115 process. Others may have 
undetected ischemic or valvular heart disease. Whether LBBB is yet another 
marker that reflects a generalized physiological aging process (for example, 
diabetes) or is more directly and causally involved in the pathway to 
cardiovascular death remains unanswered. In any case, LBBB by itself has 
been related with an adverse prognosis. Accordingly, Fahy et al, based in a 
screening program (110,000 participants, 112 with LBBB but without apparent 
or suspected heart disease, mean follow-up of 9,5 years) reported that it was 
associated with an increase prevalence of cardiovascular disease at follow-up 
(21% vs 11%; p=0,04)116. Nevertheless, population presented here is somehow 
different to the previous studies above mentioned. On the one hand they are not 
healthy subjects, but AF patients with associated cardiovascular disease 
(82,7% with AHT), and as it is known, AF and HF are inextricably linked, as 
both share common risk factors and each increases the risk of the other. But on 
the other hand they do not present symptoms of HF or impairment on the 
ventricular function. In any case, caution must be exercised in this particular 
population due to several reasons. First of all, the abnormal pattern of 
ventricular depolarization associated with LBBB can induce or exacerbate 
systolic and diastolic left ventricular dysfunction and may thus compound the 
effects of concomitant myocardial disease117,118. Secondly, the presence of 




attendant complications after further insults from ischemia, infarction, negatively 
dromotropic drugs, or age-related conduction-system degeneration. In addition, 
a prolonged QRS duration may be a marker of cellular uncoupling. Myocardial 
fibrosis or ischemia-related conduction delay could result in QRS widening and 
an increased susceptibility to re-entrant tachyarrhythmias120,121. Accelerated 
QRS widening may not only increase electrical instability but also lead to 
progressive electromechanical remodelling, which may increase the ventricular 
dyssynchrony. Nevertheless, it must be underlined that prognosis could be 
different according to the degree of mechanical dyssynchrony induced by the 
LBBB, and only those patients that achieve a certain amount of mechanical 
dyssynchrony, may develop symptomatic HF122. This could have been one of 
the reasons that explain the similar outcome in this particular subgroup of 
patients. Another explanation could have been the fact that the vast majority of 
patients  (85,1%) were under therapy with CEI/ARB agents, something that 
could have had relevance in the rate of hospitalizations. In the general 
population of hypertensive patients with AF, results from the LIFE study 
reported than compared with atenolol, losartan-based therapy improved major 
cardiovascular outcomes: the occurrence of the primary composite endpoint of 
cardiovascular mortality, stroke, and myocardial infarction was reduced by 42%, 
as were its components (42% reduction in cardiovascular death and 45% 
reduction in stroke), and there was a trend towards lower all-cause mortality. In 
the Atrial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular 
Events – Irbesartan arm (ACTIVE I) in 9016 patients with AF and risk factors123, 
therapy with Irbesartan did not reduce the primary composite endpoint of stroke, 






hospitalizations for heart failure. If this is the case in patients with AF and LBBB 
remains to be elucidated124, but reassuring results are provided in the present 
study. Further studies are warranted in order to confirm the presented results. 
Thus far, in those patients with AF, LBBB without HF under optimal medical 
treatment, regular follow up could be safely recommended.  
 
"Outcomes of a contemporary sample of patients with atrial fibrillation taking 
digoxin": Results from the AFBAR study". 
Based also on data from the AFBAR study, we aimed to assess and compare 
the effect of digoxin on clinical outcomes in patients with AF versus those under 
betablokers (BB) or none. Despite negatives results in previous studies, we 
hypothesized that digoxine could be an useful drug in a subgroup of patients, 
without deleterous effect (in terms of cardiovascular mortality and hospital 
admissions). We found that digoxin was not associated with increased all-cause 
mortality, survival free of admission due to any cause and due to cardiovascular 
cause, regardless of sex and presence or absence of underlying heart failure, 
despite the fact of being patients of higher risk.    
Digitalis is the oldest compound in cardiovascular medicine that continues to be 
used in contemporary clinical practice125. While it has beneficial effects in HF 
and can reduce resting heart rate in AF, some reports have indicated that it use 
may be an independent risk factor for death130. This is particularly relevant 
nowadays since other safe and inexpensive alternatives such as BB or calcium 
blockers are readily available. Some studies have been recently published in 




increased mortality among digoxin-treated patients. The first one, “The Registry 
of Information and Knowledge about Swedish Heart Intensive care Admissions” 
(RIKS-HIA) examined 1-year outcomes from patients on digoxin with AF, CHF, 
or both, by comparing them to a matched group of patients who were not 
receiving digoxin. The 4426 patients with AF and no history of HF taking digoxin 
had a significant increase in the overall mortality (EHR 1.42, 95% CI 1.29–1.56) 
compared with 16587 controls at discharge (importantly, no such difference was 
seen in patients with AF and HF, or in patients with heart failure without AF). In 
the AFBAR study, EHR matched the one describe in the RIKS-HIA, although 
with wider confidence interval. We cannot rule out that a higher sample size 
could have translated in narrower confidence interval. However, some 
differences are notable between both studies. First of all, RISK-HIA was 
performed in an intensive care setting, which makes it difficult to extrapolate the 
results. Secondly, It only analyzed total mortality based on a national survey, 
and finally the follow up was 1 year versus the mean 2,9 years done in the 
FABAR.  
The second one, a recent sub-study of the AFFIRM131, reported that in patients 
with AF, digoxin was associated with increased all-cause mortality after 
controlling for comorbidities and propensity scores, regardless of sex and the 
presence or absence of underlying HF. Hence, all-cause mortality was 41% 
higher in patients on digoxin, discouraging in some way rate control with digoxin 
as a single first line agent. “The Stockholm Cohort study on Atrial Fibrillation 
(SCAF)”127, showed that Digoxin is mainly given to an elderly and frailer subset 
of patients with AF, moreover, when these and other differences in patient 






term mortality and major cardiovascular events in patients with AF. 
Consistently, results from the AFBAR study also showed that digoxin is 
prescribed in high risk patients, even though digoxin appears to have a neutral 
effect on long-term mortality (EHR 1.42; 95% CI 0.77–2.60, p= 0.2), admission 
due to any cause (EHR 1,03; 95% CI 0,71-1,49, p= 0,8), and admission due to 
cardiovascular cause (EHR 1,19; 95% CI 0,72-1,96, p= 0,4), after accounting 
for age, comorbidity and other patient characteristics. The analysis was 
consistent when it was performed over the entire cohort (those patients under 
digoxin, BB, both or none) and when they were divided as those under 
exclusively digoxin or BB. However, in terms of global survival, the group under 
BB plus digoxin showed a trend towards a worse outcome than those under BB, 
digoxin or none. Although no final conclusions can be given in this regard 
because it is based on a small number of patients (n=58), this is important since 
it was postulated that beta-blockers could attenuate digoxin's neurohormonal 
effects. However, when patients were divided as those presenting HF or not, 
there were no significant differences in relation to the survival between groups. 
Moreover, this difference could be explained in part because this subgroup 
represents a frailer subset of patients (higher rate of DM and HF). Anyhow, it’s 
our opinion that it deserves further investigation in order to rule out any kind of 
causality. 
In our study we have tried to highlight the differences between the AFBAR study 
versus the landmark study performed in the setting of digoxine use; the AFFIRM 
study
14
. For instance, the AFBAR population was older than the one described 
in the AFFIRM (74,8 versus 69,7 years old), and also the rate of women (46,9 




disease was the predominant cardiac diagnosis in a 17,5% in the AFBAR 
versus a 26,1% in the AFFIRM. Digoxin was used as monotherapy for rate 
control in 34,7% in the AFBAR versus 17% in the AFFIRM. The rate of renal 
disease was 9,6% in the AFBAR and around 5,5% in the AFFIRM. The rate of 
diabetes mellitus was not specified in the AFFIRM study, but was considerable 
high in our study population (26,5%). These reasons could explain the 
differences found in the survival rates (16,5 in the AFFIRM versus 11,9 in the 
AFBAR) during a similar follow up period (around 3 years in the AFBAR and 3,5 
in the AFFIRM).  
On the other hand, a comparison between Lenient versus Strict Rate Control II 
(RACE II) showed that when compared with strict rate control, lenient rate 
control was not inferior in terms of major clinical events23. This could have 
represented a bias regardless the drug selected, both in the AFFIRM and 
AFBAR studies. Unfortunately, as we pointed out, strict versus lenient control 
was not specifically compared in the AFFIRM, although a heart rate of more 
than 100 beats per minute was found to have an effect on all-cause mortality 
and cardiovascular mortality (EHR 2.92; 95% CI 2.21–3.85, p= 0.0001 and 
2.31; 95% CI 1.53–3.50, p= 0.0001 respectively). Heart rate was not available 
in our database, thus differences adjusted for heart rate could not be assessed 
in our study population. 
In regard to patients with HF, prior studies with digoxin in patients with chronic 
HF reported improvements in LVEF134-135, HF symptoms136,137 and exercise 
performance134. Despite the fact that the DIG study140 excluded patients with 
AF, it was the largest trial that examined the safety of digoxin in patients with 






have a neutral effect on the all-cause mortality (EHR 0.99; 95% CI 0.91–1.07; P 
= 0.80) but reduced the rate of hospitalizations for HF. Further analysis of the 
DIG trial data demonstrated that digoxin’s beneficial effect only applied to 
patients in sinus rhyhtm with low serum digoxin drug levels (0.9 ng/mL). It 
should be highlighted that frequent monitoring of serum digoxin concentrations 
was performed in the DIG trial. This is relevant because as it is known, positive 
inotropic and neurohormonal effects are attained with low plasma drug 
concentrations, and as the DIG trial reported, patients with higher digoxin levels 
had worse outcomes140. Singh Dhaliwal et al, on a cohort of heart failure 
patients (n=347, 155 of them treated with digoxin), failed to show a reduction in 
HF hospitalizations or to show any benefit in subgroups of patients with severe 
LV systolic dysfunction with LVEF < 25% or NYHA class III or IV141. Notably, 
this study population was older, with a higher proportion of patients with NYHA 
class III or IV HF, and more co-morbid medical conditions, particularly diabetes 
and hypertension. In the AFBAR study, survival, morbidity and cardiovascular 
mortality were not higher in those patients with the clinical diagnosis of HF 
dispensed to digoxin. Of the 95 patients with HF, 29 (30,5%) died during the 
follow-up period. Digoxin was not associated with all-cause mortality (EHR 0,94; 
95% CI 0.20–4,41, p = 0.9), admission due to any cause (EHR 1,02; 95% CI 
0,37-2,82, p=0,9) and due to cardiovascular cause (EHR 0,64; CI 95% 0,22-
1,86, p=0,4). Consistent with the current evidence, those patients with HF 
without BB had a significant worse outcome (in terms of hospital admission due 
to cardiovascular cause) than those under BB, but also than those under 




Finally, it should be pointed out that in our study, a sex interaction was not 
found with digoxin therapy. Post hoc analysis of the Digitalis Investigation 
Group indicated that digoxin, when used in the treatment of HF, may increase 
mortality by approximately 20% in women but not in men142. Nevertheless, this 
has not been confirmed in other observational studies. For instance, a study 
conducted using the Health Information Network population database143, aimed 
to study the impact of digoxin exposure on mortality for men and women who 
carry the diagnosis of HF (n=10808 women), showed absence of a large 
interaction between digoxin use and sex affecting mortality; Consistent with the 
AFBAR and the Health Improvement Network Database are two prior 
observational studies that also did not point out any digoxin sex 
interaction144,145. Because the finding of an interaction from the DIG trial was the 
result of post hoc analysis, it has been postulated that it could be conceivable 
that the finding was a type 1 error (false positive) interaction143, but it is also 
possible that the DIG trial results were correct, and the observational results are 
biased by unmeasured confounders that affected the interaction analysis. 
Besides, it has also been reported that interventions known to reduce mortality 
in HF are used less in women than in men143, that although could be due to 
male and female populations with HF that might legitimately affect prescribing 
practices, it deserve further investigation. 
To sum up, we concluded that, based on the current evidence, there are still 
doubts regarding the contemporary role of the digoxin, at least in the setting of 
rate control in patients with AF. Nowadays digoxin is indicated in the current 
guidelines in patients with heart failure and LV dysfunction, and in sedentary 






evidence “C”3. Evidence in these regards is still a matter of controversy. While 
sub studies of the AFFIRM131 raised safety concern, results from the AFBAR 
study did not show any association between digoxin with increased all-cause 
mortality and hospital admissions, regardless of sex and the presence or 
absence of underlying HF. It is our belief that further studies are required in 
order to ensure the current role of digoxin in the management of patients with 
AF.  
 
Failure of hybrid therapy for the prevention of long-term recurrence of atrial 
fibrillation 
Based on our consecutive series of patients with typical AFl who successfully 
underwent radiofrequency catheter ablation at our hospital between November 
1998 and May 2010, we tried to determine the long-term effectiveness of the 
hybrid therapy (management strategy that consists of the ablation of CTI and 
continued pharmacologic therapy with Class I or III AAD) in the control of AF as 
well as the differences in clinical outcomes between patients with antiarrhythmic 
drug AFI, those with coexistent AFl and AF, and isolated AFl. We postulated 
that this so-called “hybrid therapy”, presently established in the ESC guidelines, 
is not a very effective therapy for long-term control of AF. The main finding of 
our study was that a hybrid pharmacological and ablative therapy for AAD-AFl 
often fails if the follow-up period is sufficiently long, with AF recurring in the 
majority of the patients (74%, IDR: 19.1/100 person-years). This incidence rate 
was similar to the recurrence rate of AF in patients with coexistent AFl and AF 




clinical outcomes and recurrence of AF were similar between Group 1 (AAD-AFl 
patients) and Group 2 (patients with coexisting AF and AFl). Both of these rates 
were significantly higher than the occurrence of AF in the isolated AFl group 
(Group 3) (33%, IDR: 7.9/100 person-years). As we pointed out in the 
publication, our results are likely to be conservative due to the possibility of 
hidden asymptomatic recurrences. The EHRA score of AF recurrent episodes in 
the AAD-AF group was 2.00. Therefore, some of the AF recurrences may not 
have been detected.  
Previous studies have shown hybrid therapy to be an effective method for 
managing AAD-AFl in the short-term150-152,155-156. Reithman et al153 reported an 
AF recurrence rate of 20% in AAD-AFI patients during a 8-month follow-up 
period compared with a 76% recurrence rate in patients with coexistent AF and 
AFl prior to CTI ablation. Huang et al. reported an AF recurrence rate of 11% in 
an AAD-AFl series underwent CTI ablation, in a 14-month follow-up period152, 
and in the largest series of AAD AFI patients (90 patients), Reithman et al. 
reported an AF recurrence rate of 27% at 16 months post-ablation and 33% at 
21 months post-ablation151. Another study reported that AF recurred in 42% of 
the 72 AAD-AFI included in their study during a 24 month follow-up period, 
much lower than the recurrence rate of 78% that was detected in a group of 
patients with prior AF155. Given the shorter follow-up times compared with our 
study, the higher AF recurrence rate observed in our hybrid therapy series156 
could be due at least in part to the longer follow-up period. 
In our study, the AF rate was higher during the first 5 years of followup but then 
continued at a steady rate until the last follow-up time point. In a study with a 5-






cumulative incidence similar to that found in our series
157
. A study by Turco et 
al. included 154 AAD-AFl patients who developed AFI after intravenous infusion 
of 42% during a 2-year follow-up period and 47% during a 4.5-year followup 
period
158
. In agreement with this result, Hirao et al. reported an AF recurrence 
rate as low as 25% in a CTI AAD-AFl ablation cohort of 17 patients treated with 
oral pilsicainide during a 3-year follow-up period
159
. Both figures are extremely 
low, even lower than the AF recurrence rate in some isolated AFl series
160-163
 
[15–18]. AAD withdrawal during follow-up may also contribute to the high AF 
recurrence rate observed in our study. Only 33% of the patients in the AAD-AFl 
group were receiving AAD treatment at the end of the follow-up period 
compared with 100% immediately following ablation, and 42% in the coexistent 
AF group were receiving AAD treatment at the end of the follow-up period 
compared with 64% immediately following ablation. Nevertheless, AAD 
withdrawal is unlikely be a determinant factor because a low AF recurrence rate 
was reported in a study with a short follow-up time period despite the cessation 
of AAD therapy in 25% of the patients due to adverse effects and a change in 
AAD treatment in 33% of the patients due to a lack of treatment efficacy
153
. In 
another series with a 5-year follow-up period, all of the patients continued to 
receive AAD treatment throughout the study, and the AF recurrence was 
90%
157
. Therefore, the AAD effect was modest even in the short-term. In our 
study, 51% of the patients were in permanent AF 6 years post-ablation.  
Differences in the definition of AAD-AFl could also help explain the variation in 
the reported AF rates. In our study, we only included patients who developed 
AFl secondary to either intravenous or oral administration of AAD (amiodarone, 




6.6%. The study by Anastasio et al. included patients who were initially 
diagnosed with AF and AFl (15%); the reported incidence of AAD-AFl was 
18.4%157. Although the definition of AAD-AFl might have contributed to the 
differences in reported AF recurrence rates, we believe that the length of follow-
up is more likely to affect the recurrence rate since the two series with the 
longest follow-up had similar results157.  
Long-term follow-up and a thorough search for AF (e.g., clinical visits, Holter 
monitoring, implantable devices, transtelephonic monitoring) are the key factors 
in determining the real AF recurrence rate after CTI ablation. A study with a 21-
month follow-up that used event recorders and 7-day Holter monitoring, 
reported an AF recurrence rate of 74% in a group of coexistent AF patients who 
underwent CTI ablation with AAD treatment and an 81% AF recurrence rate for 
patients who were no longer receiving AAD treatment165. This report 
demonstrates the superiority of pulmonary vein isolation ablation (PVI) with or 
without CTI ablation compared with CTI ablation alone in patients with 
coexistent AF and AFl as well as the modest effect of AAD treatment on the AF 
recurrence rate, although there was a selection bias because the AAD 
treatment had previously failed in all of the patients included in the study. Even 
for isolated AFl, combined PVI and CTI ablation has been shown to be more 
effective than CTI alone (87% vs. 44% of the patients were free of arrhythmia at 
the end of a 16-month follow-up period with 48 h ambulatory monitoring every 2 
months)165. In a more recent report, 20 patients with isolated AFl underwent CTI 
ablation and had a loop recorder implanted. None of these patients was 
receiving AAD therapy. After 1 year, 42% of the patients had not developed AF 






recorder can be effective in the long-term surveillance for AF, although an 
improvement in the existing technology is needed166. 
In regard to the AFI recurrence, the rate at the end of the follow-up period was 
29.6% in Group 1, which is significantly higher than the Group 2 (11.8%) or 
Group 3 (13%) rate. The AFl recurrence rate in the global population of our 
study is slightly higher than that reported in the majority of other studies160-163 . 
The type of the catheter used might explain some of the differences. In our 
study, an 8-mm-tip catheter was used in the majority of patients (97.9%), and 
an irrigated-tip catheter was only used in the remaining 2.1% of the cases. It is 
known that an irrigated-tip catheter produces greater lesions than an 8-mm-tip 
catheter167. However, we do not have a definitive explanation for the differences 
in the reported AFI recurrences rates. We do know that in our study, the 
procedure was performed in sinus rhythm more frequently in Group 1 (55%) 
than in Group 3 (30%), and the paroxysmal type of AFl was also more frequent 
in Group 1 (66.7%) than in Group 3 (39.7%). The whole of patients in Group 1 
were on AAD therapy. This could give false impression of block in the isthmus 
in the first ablation. 
And important point of our study was that the rate of stroke detected during the 
follow-up period in Group 1 was similar as the rate seen in Group 2 and a 
slightly higher stroke rate than Group 3; these results are similar to those 
reported by others168-169. Of note, all of the strokes that resulted in death had 
transitioned to AF (2 patients in Group 1, 1 in Group 2 and 3 in Group 3), 
demonstrating the worse prognosis of an AF related stroke170. 
Finally, it is important to highlight that there were a trend towards a lower 




cardiovascular disease in these patients. This trend was maintained even with 
the development of AF during follow-up despite the fact that AF is a recognized 
factor of increasing mortality171-172. 
Being aware of the abovementioned limitations, we concluded that AF recurs in 
most of the patients who receive a hybrid (pharmacological and ablative) 
therapy, and the clinical outcomes for AAD-AFI patients are similar to those of 
patients with coexisting prior AF and typical AFl. The efficacy of AAD is modest 
and can be maintained only in one third of the patients in a long-term follow-
up184.  
 
Risk of pacemaker implantation after uneventful successful cavotricuspid 
isthmus radiofrequency ablation in patients with common atrial flutter. 
In this muliticenter study, we retrospectively reviewed the electrophysiology 
laboratory database at two Spanish University Hospitals in order to identify 
patients with AF-AFl who had undergone electrophysiology study for CTI 
dependent AFI. We hypothesized that in patients with history of CTI ablation for 
common AFI, ECG Intraventricular conduction disturbance and slow ventricular 
response at the time of the ablation might be strong predictors of the need of 
PMI in the long term. As we expected, ECG Intraventricular conduction 
disturbance and slow ventricular response at the time of the ablation were 
strong predictors of the need of PMI in the long term. Interestingly, A HR of less 
than 65 bpm at the time of the ablation was identified as the optimal cut-off 
value to predict future need of PCM implantation in the follow up185.  
To the best of our knowledge, this is the first study reporting the rate of PMI 






heart rate and ECG intraventricular conduction disturbance. Not many studies 
up to date focused in this specific complication in this particular subset of 
patients with atrial arrhythmias. Sairaku et al182 reported the rate of pacemaker 
implantation but immediately after the ablation. They found that 24 patients out 
of 211 patients (11%) required a permanent PCM implantation for significant 
SND after AFI termination. In their study, females (OR 2.43; 95% CI 1.32–4.62; 
p=0.0046), left ventricular ejection fraction (LVEF) < 50% (OR, 2.10; 95% CI 
1.20–3.87; p=0.012), and AFI cycle length of > 273 ms (OR, 5.34; 95% CI 3.08 
– 10.08; p< 0.0001) were independent predictors of SND requiring PMI. The 
authors hypothesized that the AFI cycle length could reflect the extent of the 
atrial remodelling: the more remodelling, the slower the conduction velocity. In 
our study flutter cycle length was also slower in patients requiring PCM 
implantation but it was not an independent predictor in the multivariate analysis. 
Nevertheless, some differences should be mentioned between these two 
studies. First of all, Sairaku et all182 focused on the risk of PCM implantation 
immediately after the ablation. We evaluated the risk of PCM implantation in the 
long-term follow up, with a noteworthy follow up. Secondly, we took into 
consideration other reasons for PCM implantation, such as AV conduction 
disease or slow conducting AF.  
From our point of view, it is reasonable to think that patients with slow 
ventricular response during the AFI could be subtle AV conduction dysfunction; 
not only physiologic, unmasked by the stress over the AV node impose by the 
AFI. As a matter of fact, HR at the time of the ablation was an independent 
predictor for the need of PCM implantation. This risk was particularly higher 




the time of the ablation was identified as the optimal cut-off value to predict 
need of PCM implantation in the follow up (sensitivity 79% and 74% specificity), 
regardless of the presence of rate-control drugs. As it is known, although 2:1 A-
V conduction is common during AFI, variable A-V conduction (e.g., 4:1 or 6:1) 
can be seen frequently, but at the present time there is lack of evidence 
regarding the level of block in these situations. On the one hand, Josephson 
and co-workers reported that block below the His can also be observed, but on 
the other hand the same group stated that intra- or infra-His block during atrial 
flutter is usually physiologic because refractoriness in the His-Purkinje system 
exceeds the flutter cycle length183. Unfortunately due to retrospective 
characteristic of our study we could not evaluate the level of the block so it 
cannot be concluded whether the risk of PCM implantation depends on its level. 
However, based on the fact that more that half of the patients requiring PCM 
implantation presented some degree of intraventricular conduction disturbance 
in the baseline ECG, it could be suggested, as a hypothesis, that the level of the 
block could have played a role. In any case, it is our opinion that from a clinical 
point of view, baseline HR and ECG Intraventricular conduction disturbance 
could be simple clinical markers to be taken into account by the physician since 
management of these patients is subject to relevant changes. For instance, to 
start with, these patients could require more cautious monitoring with special 
attention to the development of syncope, dizziness or dyspnoea. Secondly, it 
also should be taken into account at the time of the prescription of rate-control 
drugs that could impair sinus node function or AV conduction.  
As aforementioned some limitations in the study merit comment. First, 






confounding. However, consecutive patients who underwent CTI radiofrequency 
ablation were included and follow-up was performed according to a uniform 
protocol. Moreover, the non-randomize nature of the study does not allow us to 
conclude which strategy (ablate or pace) should be chosen in this subgroup of 
patients. Probably, it could be hypothesized that restoration of sinus rhythm 
could be beneficial for the AV synchrony and the potential thromboembolic risk 
of the atrial flutter. But it is our opinion that these points should be specifically 
addressed in futures studies. Secondly, we have enrolled patients with 
‘persistent’ AFI; had it been performed in patients with shorter AFI duration, the 
degree of remodelling may have been less with the potential repercussion over 
the right atrium and the sinus node function. However, the duration of persistent 
or chronic AFI may be at times difficult to define accurately due to the 
misinterpretation of the symptoms. Thirdly, as it is already known, AFI cycle 
length is affected by the autonomic tone. Therefore, not conducting an 
autonomic blockade was a major limitation of our study. On the other hand, 
although patients who presented complete auriculoventricular block by an 
inadvertent application of energy on the normal AV conduction system were 
excluded, we cannot rule out the damage of the AV conduction system during 
the RF applications. Furthermore, coronary angiography was not performed in 
those patients so it cannot be excluded intended and unidentified damage of the 
right coronary artery during the application.   
Heart rate measurement may not reflect the heart rate range or average heart 
rate of the patient and may be too crude to be a reliable indicator of risk.  
Finally, patients who had a previous PCM were not included in our study. This 




AFI and clinically significant SND or AV conduction disease. Subsequently, 
further studies with more number of patients and events will be needed in order 
to ascertain the real relevance and management of the problem.  
All in all, with this study, we highlighted the important association between 
baseline ECG intraventricular conduction disturbance and heart rate pre 
ablation and the subsequent risk of PCM implantation. However, this point is not 
mentioned in the current recommendations for the management of patients with 
AF – AFl. As a matter of fact although both diseases share the same 
recommendations
3
, some intrinsic differences between both substrates are 
present. Hence, in light of our major finding, therefore, assessing it prior to 
ablation can be helpful for the risk stratification of SND or AV conducting 












































 AF prevalence has increased over the last decade. This increase is due to 
the higher prevalence of AF in people over 70 years old. Moreover, the 
current AF population exhibits a higher risk profile for thromboembolic 
events because of the higher prevalence of hypertension, diabetes, CAD, 
LVH, previous stroke and HF. Regarding medical treatment, firstly more 
aggressive antithrombotic treatment has been observed, as well as radical 
changes in the use of oral anticoagulants, reversing the decreasing use in 
elderly patients observed in 1999. 
 The new recommendations (CHADASVASc versus CHADS2) will result in a 
significant increase in patients with indications for OAC, at the expense of 
those previously characterized as low-to-moderate risk.  
 AF could be one of the first clinical manifestations of latent BS in a 
considerable number of patients. In this setting, ajmaline challenge plays an 
essential role, mainly in young patients with a family history of sudden death, 
despite having normal findings on a baseline electrocardiogram. 
 In AF patients without HF nor LV dysfunction, after adjusting for potential 
confounders, LBBB was not predictive of all-cause death, admission to any 
cause or cardiovascular cause. 
 Digoxin was not associated with increased all-cause mortality, survival free 
of admission due to any cause and due to cardiovascular cause, regardless 
of gender and presence or absence of underlying HF, despite the fact of 
being patients of higher risk. 
 AF recurs in most of the patients who receive a hybrid (pharmacological and 






to those of patients with coexisting prior AF and typical AFl. The efficacy of 
AAD is modest and can be maintained only in one third of the patients in a 
long-term follow-up. 
 In our non-trial-based cohort of patients with a history of CTI ablation for 
common AFI, ECG intraventricular conduction disturbance and slow 
ventricular response at the time of the ablation were strong predictors of the 
need of PCM implantation in the long term. A heart rate of less than 65 bpm 
at the time of the ablation was identified as the optimal cut-off value to 






 La prevalencia de FA ha aumentado significativamente en la última década. 
Este incremento es a costa principalmente de pacientes de más de 70 años. 
Además, la población actual representa un mayor perfil de riesgo de 
eventos tromaboembólicos debido a una mayor presencia de hipertensión 
arterial, diabetes mellitus, enfermedad coronaria, hipertrofia ventricular 
izquierda, accidentes cerebrovasculares e insuficiencia cardiaca. En lo 
referente al tratamiento médico, se aprecia un aumento en el uso de los 
fármacos anticoagulantes y una disminución en el uso de antiagregantes. 
 Las nuevas recomendaciones (CHADASVASc versus CHADS2) resultarán 
en un incremento significativo en las indicaciones de anticoagulación oral, a 
expensas de aquellos previamente caracterizados como de riesgo bajo-
moderado.  
 La FA puede ser una de las primeras manifestaciones clínicas en pacientes 
con un síndrome de Brugada latente. Por lo tanto el test de ajmalina puede 
desempeñar un papel fundamental, principalmente en sujetos jóvenes con 
historia de muerte súbita, a pesar de presentar un electrocardiograma basal 
normal.  
 En pacientes con FA sin insuficiencia cardiaca ni disfunción ventricular 
izquierda, despues de ajustar por posibles factores confusores, el bloqueo 
de rama izquierda no es predictor de mortalidad de cualquier causa, 
ingresos de cualquier causa ni de causa cardiovascular. 
 En pacientes con FA, la digoxina no se asocia con un incremento de la 






independientemente del sexo y la presencia de insuficiencia cardiaca, a 
pesar de ser éstos pacientes de más alto riesgo.  
 En pacientes con FA que desarrollan un fluter auricular tipo IC, la estrategia 
híbrida (ablación del istmo cavotricuspídeo y mantenimiento de los fármacos 
antiarrítmicos) se asocia con una alta recurrencia de la FA (dos tercios de 
los pacientes), por lo que debería valorarse en este contecto la ablación 
combinada del istmo cavotricuspídeo y de venas pulmonares.  
 En pacientes con FA/flutter auricular e historia de ablación del istmo 
cavotricuspídeo, la presencia de trastornos de la conducción intraventricular 
basal y una baja frecuencia cardiaca al momento del implante (en concreto 
flutter auricular con respuesta ventricular < de 65 lpm) son predictores 
significativos de requerimiento de implante de marcapasos durante el 






























SUMMARY - RESUMEN 
En la presente tesis se intentan evaluar aspectos importantes a nuestro 
parecer referentes al manejo integral de los pacientes con fibrilación 
auricular (FA) que actualmente no están contemplados en las guías de 
prática clínica. Para elaborar dichas observaciones nos hemos apoyado en 
diferentes bases de datos de pacientes con FA, nacionales e internacionales 
que nos han llevado a publicar dichos resultados en revistas médicas.  
En primer lugar y casi a modo de introducción de los resultados que se 
presentan posteriormente consideramos relevante evaluar la tendencia en la 
prevalencia y el manejo farmacológico de los pacientes con FA en la última 
década. Para ellos nos basamos en dos estudios transversales realizados el 
primero de ellos en 1999 y el segundo en 2009. Dicho estudio parece indicar 
que la incidencia de FA ha aumentado significativamente en la última 
década. Además, la población con FA muestra un perfil de riesgo 
tromboembolico más adverso (mayor prevalencia de hipertensión arterial, 
diabetes mellitus, enfermedad coronaria, hipertrofia ventricular izquierda, 
ictus previos e insuficiencia cardiaca). Esto ha llevado entre otros motivos a 
un cambios radical en el uso de fármacos anticoagulantes y antiagregantes. 
A su vez, dado el cambio en las recomendaciones para la estratificación del 
riesgo tromboembólico (CHADASVASc versus CHADS2), pretendimos 
evaluar en la misma población la relevancia que en nuestro medio tendrá 
dicha recomendación a la hora de prescribir fármacos anticoagulantes. El 
resultado de dicho estudio indica que esta nueva escala supondrá un 
incremento notable en la indicación de anticoagulación oral a costa 




como de riesgo bajo-moderado. Por lo tanto, es nuestra opinion que la 
evaluación del riesgo hemorrágico deberá ser tenido en cuenta ahora más 
que nunca para prevenir los efectos colaterales que supone el incremento en 
la prescripción de anticoagulantes orales en base a las nuevas 
recomendaciones.  
Dejando a un lado la epidemiología de la enfermedad, nos centramos 
posteriormente en la etiología de la FA. Numerosas causas han sido 
atribuidas en la génesis de la FA y aparecen consecuentemente detalladas 
en las guías de práctica clínica. Sin embargo la presencia de una 
canalopatía latente (síndrome de Brugada) con la consiguiente 
vulnerabilidad auricular no aparece mencionada entre ellas. Para nostros 
esta relación representa un cuestión crucial puesto que en dicho caso el 
tratamiento farmacológico y el abordaje del paciente (y familiares) es 
completamente diferente al manejo de los pacientes con FA “solitaria” o 
secundaria a otras causas. Por lo tanto, en base a los resultados de nuestro 
estudio en el que se registró que una pequeña proporción de pacientes con 
FA presentan síndrome de Brugada latente, nosotros abogamos por la 
realización de test de bloqueantes de los canales de sodio en pacientes con 
fibrilación auricular jóvenes sin causa aparante, y especialmente cuando 
presentan antecedentes familiares de muerte súbita.  
Independientemente de la etiología también nos pareció relavante abordar la 
cuestión de cual es la relevancia de la presencia de bloqueo de rama 
izquierda en pacientes con FA y sin disfunción ventricular izquierda. Hasta la 
fecha no se ha evaluado dicho aspecto lo cual es relevante a la hora de 






población, tras ajustar por potenciales factores confusores, la presencia de 
bloqueo de rama izquierda no fue predictor de mortalidad de cualquier 
causa, hospitalización de origen cardiovascular o de cualquier causa.  
Centrándonos posteriormente en el tratamiento farmacológico de los 
pacientes con FA, creemos que es relevante evaluar (por primera vez) en 
nuestro medio la seguridad de la digoxina en éste ámbito. Dicho fármaco ha 
sido cuestionado recientemente en subanálisis de estudios de pacientes con 
FA y en pequeños estudios retrospectivos/meta-análisis. Cuando nosotros lo 
evaluamos de forma prospectiva en nuestra muestra de pacientes con FA 
seguidos durante 3 años, dicha medicación, a pesar de prescribirse en 
pacientes más añosos y sedentarios, no se asoció con muerte de cualquier 
causa ni supervivencia libre de ingresos hospitalarios (tanto de causa 
cardiovascular como de cualquier causa). Por lo tanto creemos que aunque 
es cierto que hay que prestar atención a ciertas peculiaridades propias de 
dicha droga, en nuestro estudio no parece haber evidencia que obligue a 
desterrar esta medicación del arsenal terapeútico de pacientes con FA. 
También en linea con el tratamiento farmacológico creímos conveniente 
evaluar la efectividad del tratamiento híbrido (farmacológico y ablación del 
istmo cavotricuspídeo) en nuestra muestra de pacientes con flutter auricular 
secundario a tratamiento antiarrítmico prescrito para control de la FA. 
Cuando se atendió a la tasa de eventos (FA, ictus, muerte) la tasa de los 
mismos fue similar a aquellos pacientes con FA sin flutter auricular. Estos 
restultados desde nuestro punto de vista suponen un cambio importante a la 




antiarrítmicos y tal vez la ablación combinada de ICT y FA sea más 
apropiada en este contexto. 
Finalmente pretendímos evaluar en dicha población de pacientes remitidos 
para ablación del ICT la tasa de requerimiento de implante de marcapasos 
post procedimiento. En dicha muestra apreciamos que la presencia de 
trastornos de la conducción intraventricular y una frecuencia cardiaca inferior 
a 65 lpm son significativos predictores de requerimiento de marcapasos post 
ablación. Esto es relevante a la hora de prescribir fármacos que puedan 
disminuir la respuesta ventricular así como planear los posteriores controles 
post ablación.  
En suma, en el presente trabajamo hemos intentado evaular de forma 
integral (epidemiología, etiología y tratamiento) aspectos relevantes para el 
manejo de pacientes con FA-flutter auricular no recogidas en las actuales 
guías de práctica clínica pero que desde nuestro punto de vista son 
relevantes y deben ser tenidas en cuenta por todos aquellos profesionales 
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